Bandaram Pharma Packtech Limited

As of June 30, 2026, Bandaram Pharma Packtech Limited carries a market capitalization of 512.20M, placing it among publicly traded companies globally. Its enterprise value stands at 512.20M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Bandaram Pharma Packtech Limited has 17.97M shares outstanding.

As of June 30, 2026, Bandaram Pharma Packtech Limited trades at a trailing price-to-earnings ratio of 45.62.

As of June 30, 2026, Bandaram Pharma Packtech Limited trades at an EV/EBITDA multiple of 13.42 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.65 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 16.56 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 512.20M versus a market cap of 512.20M, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

Over the twelve months ended June 30, 2026, Bandaram Pharma Packtech Limited recorded 4.64M in income tax expense. That works out to an effective tax rate of 28.12, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 16.50M, leaving 9.96M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Bandaram Pharma Packtech Limited's stock has declined approximately 28.41% over the past 52 weeks. The 50-day moving average sits at 19.59, while the 200-day moving average is 25.35.

Over the twelve months ended June 30, 2026, Bandaram Pharma Packtech Limited generated 787.72M in revenue and converted that into 9.96M in net income, yielding earnings per share of 0.74. EBITDA reached 38.17M, while operating income came in at 30.93M.

Over the twelve months ended June 30, 2026, Bandaram Pharma Packtech Limited posted a gross margin of 13.43, reflecting its pricing power and cost economics. The operating margin of 3.93 and net profit margin of 1.26 provide insight into operational efficiency.

Bandaram Pharma Packtech Limited's most recent stock split took place on July 3, 2023 with a 310:891 split ratio.